Table 3 Diagnostic performance and complications

Adequate tissue reported by a pathologist, n (%)

57 (74)

74 (100)

< 0.001

Diagnostic yield, n (%)

 Overall

69 (89.6)

70 (94.6)

0.406

 In mass size < 4 cm

39/47 (83)

40/43 (93)

0.146

 In mass size > 4 cm

30/30 (100)

30/31 (96.8)

1

Diagnosis following EUS-TA, n (%)

0.232

 Pancreatic adenocarcinoma

40 (51.9)

52 (70.3)

 Pancreatic neuroendocrine tumour

8 (10.4)

5 (6.8)

 Mass forming chronic pancreatitis

10 (13)

3 (4.1)

 Pancreatic lymphoma

4 (5.2)

3 (4.1)

 Pancreatic tuberculosis

2 (2.6)

1 (1.4)

 Other diseases

5 (6.5)

6 (8.1)

 Non-diagnostic

8 (10.4)

4 (5.4)

Severe adverse event, n (%)

0 (0)

1 (0.7)

0.49

Stage of disease in patient with pancreatic cancer (AJCC), n (%)

N = 40

N = 52

0.087

 I

1 (2.5)

1 (1.9)

 II

8 (20)

3 (5.8)

 III

21 (52.5)

26 (50)

 IV

10 (25)

22 (42.3)